Moreover, Lang et al. substantiated that individuals experiencing diminished levels of serum neoplasm markers (CEA, Cyfra21-1, CA19-9, and NSE) after immunotherapy demonstrated significantly protracted PFS and OS (77). This evidence concerns the gene CEACAM5 and neoplasm.